PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists [1]

New Zealand Medical Journal

Volumn 118, Issue 1220, 2005, Pages

  Davies, Andrew ^a   Metcalfe, Scott ^b   Moodie, Peter ^a   McNee, Wayne ^a  

^a Pharmaceutical Management Agency   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALAT CC; ADALAT OROS; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; FELO; FELO ER; FELODIPINE; GENERIC DRUG; NIFEDIPINE; PLENDIL ER; SIMVASTATIN;

AWARENESS; BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG MARKETING; HEALTH CARE ORGANIZATION; HUMAN; LETTER; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REGISTRATION; REIMBURSEMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 27244434595     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (16)

1. New Zealand Public Health and Disability Act 2000, Section 47 Objectives of Pharmac.
2. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. January 2001. Available online. URL: http://www.pharmac.govt.nz/pdf /opps.pdf Accessed August 2005.
3. http://www.pharmac.govt.nz/ptac.asp Accessed August 2005.
4. New Zealand Public Health and Disability Act 2000, Section 49 Pharmac to consult in implementing objectives and carrying out functions. Available online. URL: http://www.legislation.govt.nz/browse_vw.asp?content-set=pal_statutes Accessed August 2005.
5. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. January 2001. Available online. URL: http://www.pharmac.govt.nz/pdf /opps.pdf Section 4.2 Consultation. Accessed August 2005.
6. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. January 2001. http://www.pharmac.govt.nz/pdf/opps.pdf Section 3.3.3 "PHARMAC will carry out appropriate consultation on the classification of pharmaceuticals into therapeutic sub-groups and its application of reference pricing in respect of a particular sub-group." Accessed August 2005.
7. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics. 2002;20:577-91.
8. Curt Furberg, personal communication, 2005.
9. Gribben B. Analysis of DHP CCB Claim Forms. RNZCGP Research Unit, University of Auckland; 1999.
10. Schneeweiss S, Soumerai SB, Maclure M, et al. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003;74:388-400.
11. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensinconverting-enzyme inhibitors. N Engl J Med. 2002;346:822-9. Available online. URL: http://content.nejm.org/cgi/reprint/346/11/822.pdf Accessed August 2005.
12. Medsafe email to PHARMAC, 1 August 2005.
13. Glasser SP, Jain A, Allenby KS, et al. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group. Clin Ther. 1995;17:12-29.
14. Glasser SP, Ripa SR, Allenby KS, et al. The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study Group. Clin Ther. 1995;17:296-312.
15. MedSafe. Guidance notes for applicants for consent to distribute new and changed medicines and related products, October 2001. Section 6.9 Technical Guidelines to be followed. Available online. URL: http://www.medsafe.govt.nz/reg.htm Accessed August 2005.
16. Stewart Jessamine (Medsafe), 5 August 2005